After quietly huddling in 2015 while it filled out its C-suite and lined up a manufacturing deal, Tizona Therapeutics Inc. went on the offense with a fast break into immunotherapy, scoring a $43 million series B round. The financing was co-led by Abingworth and Canaan Partners with investments from Lightstone Ventures and existing series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and Interwest Partners.